Literature DB >> 31939393

Outbreaks of dengue in Central India in 2016: Clinical, laboratory & epidemiological study.

Shraddha Tiwari1, Mohan K Shukla1, Gyan Chand1, Lalit Sahare1, Mahendra J Ukey1, Piyush Joshi1, Rameshwar Khedekar1, Neeru Singh1, Pradip V Barde1.   

Abstract

Background & objectives: Dengue virus (DENV) causes outbreaks and sporadic cases in tropical and subtropical countries. Documenting intricacies of DEN outbreaks is important for future interventions. The objective of this study was to report clinical, laboratory and epidemiological features of DEN outbreaks reported in different districts of Central India in 2016.
Methods: In 2016, outbreaks (n=4) suspected of DEN were investigated by rapid response team. Door-to-door fever and entomological surveys were conducted. Blood samples were collected and tested using NS1 or IgM ELISA; real-time reverse transcription-polymerase chain reaction was done to identify serotypes of DEN virus (DENV). NS1-positive samples were tested for the presence of IgG by ELISA. Clinical and demographic data were collected and analyzed.
Results: Outbreaks occurred in both urban and rural areas in monsoon season and Aedes aegypti was identified as the vector. Fever, chills, headache and myalgia were the major symptoms; no fatality was recorded. Of the 268 DEN suspects, 135 (50.4%) were found serologically positive. DEN positivity was higher (n=75; 55.56%) among males and in the age group of 16-45 yr (n=78; 57.8%). DENV 3 followed by DENV 2 were detected as the major responsible serotypes. High attack rates (up to 38/1000) and low cumulative IgG prevalence (14.9%) were recorded in rural areas. Interpretation & conclusions: Our study showed that DENV 3 was the major serotype responsible for outbreaks that occurred in monsoon. High attack rates and lower number of secondary infections in rural areas indicated that DENV is emerging in rural parts of Central India. Early diagnosis at local level and timely intervention by mosquito control activities are needed to avoid such outbreaks in future.

Entities:  

Keywords:  Attack rate - dengue outbreak - rural Central India - serotypes

Mesh:

Substances:

Year:  2019        PMID: 31939393      PMCID: PMC6977364          DOI: 10.4103/ijmr.IJMR_1315_18

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


Dengue (DEN) is a mosquito-borne viral disease widespread throughout the tropical and subtropical areas. Dengue virus (DENV) is transmitted by Aedes species of mosquitoes1. Four distinct serotypes of DENV (DENV-1, DENV-2, DENV-3 and DENV-4) are known to exist, although these are closely related but infection with one serotype provides only partial and short-lasting immunity; subsequent infection with different serotype in future can lead to severe symptoms2. According to a recent global estimate, 390 million people are infected with DENV per year, of whom about 100 million manifest clinically. According to another estimate, people staying in 128 countries are at risk of DENV infection3. In recent years, outbreaks from several parts of the world such as USA, China, Japan, Pacific Island countries, Western Pacific regions, Solomon island, the African regions etc., have been repeatedly reported3. WHO Regions of South East Asia and the western Pacific represent about 75 per cent of the current global burden of DENV infection4. In comparison with other Asian countries, DEN was not widespread in India before 1990s although first outbreak of DEN was reported from Kolkata in 19634. Prevalence of DEN has significantly increased since 2001; in addition to an increase in number of cases and severity of illness, its geographical range has also been shifted drastically and is now spreading to rural areas4. A recently published meta-analysis showed that more than two dozen DEN outbreaks were reported from India till 2017; most of these were reported from southern States and most occurred after 20005. In 2016, as per National Vector Borne Diseases Control Programme (NVBDCP), India has reported 110,000 cases along with 227 deaths. Madhya Pradesh (MP) has a contribution of 3134 cases and 12 deaths among them6. India is known for its hyperendemicity of DEN with the occurrence of both sporadic cases and outbreaks resulting due to infection with DENV belonging to different serotypes, moreover co-infections are also reported78. Northern India had a major outbreak of DENV 2 in 1996; subsequently, in post-epidemic period, DENV 1 was detected from the same area789. In 2003, DENV 3 emerged as dominant serotype in Delhi and other parts of north India while recently all four serotypes are reported circulating789. A nine-year trend study from Mumbai, western India showed dominance of DENV 2, followed by DENV 1 and about three per cent co-infection10. Studies done till 2017 showed DENV 2 and DENV 3 as dominant serotypes in the southern region, and DEN 1 and DEN 2 in the eastern India5. Circulation of all the four serotypes of DENV has already been reported from Central India, and outbreaks of DENV 1 and 2 have been documented911121314 from tribal and rural areas1112. It has been documented that DENV 2 infection is more severe and is commonly associated with DEN haemorrhagic fever (DHF) and mortality than DENV 1 and DENV 41115. Hospitalization rates were found to be higher in DENV 3-infected patients than in DENV 1-infected patients16. This study was undertaken to present the information on four DEN outbreaks investigated in different districts of Central India (MP) in 2016, elaborating the clinical, laboratory, epidemiological and entomological aspects of DEN disease.

Material & Methods

Outbreak areas and field surveys: In 2016, clusters of cases suspected of DEN were noticed in rural areas of Damoh (population: 14,990), Morena (population: 1236), Sehore districts (population: 2207) and in the urban area of Katni district (population: 15,000)17 of MP, India. The rapid response team (RRT) of the ICMR-National Institute of Research in Tribal Health, Jabalpur (NIRTH), Jabalpur, comprising clinician, entomologist and epidemiologist along with the support staff visited these areas. Door-to-door fever and entomological surveys were conducted in the affected areas as per NVBDCP guidelines6. The case definition given by NVBDCP for DEN was followed. DEN suspects were identified and guided to health camp where they were clinically examined and blood samples (2-3 ml) were collected. The study was performed after obtaining clearance of the Institutional Ethics Committee (approval no: RMRCT/Ethics committee/2715/2011) and written informed consent was taken from the patients. Clinical and demographic data were collected in predesigned format. All the blood samples were transported to the Virology laboratory of NIRTH maintaining cold chain. The mosquito control measures were initiated immediately. Collected adults and larvae of mosquitoes were transferred to the laboratory and identified using standard key18. The incidence was labelled as outbreak as defined by NVBDCP that is more than five cases reported from a village or a locality with 10-15 thousand population, within a week6. Sample processing ELISA: Serum was separated from blood sample. Samples collected in acute phase of illness (0-5 days, n=137) were tested for the presence of DENV NS1 antigen by ELISA (Panbio DEN Early ELISA, Standard Diagnostics Inc., Gyeonggi, Republic of Korea). The samples collected after 5th day of onset of illness (n=131) were tested for DENV-specific IgM by monoclonal antibody-based kit manufactured by National Institute of Virology (NIV), Pune, India. Samples collected after five days of illness were also tested for the presence of chikungunya virus (CHIKV)-specific IgM antibodies using kit manufactured by NIV, Pune. All the NS1-positive samples were tested for the presence of IgG for DENV using kit Panbio Dengue IgG Capture ELISA (Standard Diagnostics Inc., Gyeonggi, Republic of Korea), following manufacturer's protocol (Figure).
Figure

Flowchart depicting algorithm testing of samples. †One NS1-positive samples could not be tested by real-time reverse transcription-polymerase chain reaction for serotyping due to insufficient sample quantity.

Flowchart depicting algorithm testing of samples. †One NS1-positive samples could not be tested by real-time reverse transcription-polymerase chain reaction for serotyping due to insufficient sample quantity. Serotyping: Acute phase samples found positive by NS1 ELISA (n=59) were subjected to serotyping, using Centers for Disease Control and Prevention (CDC) developed real-time reverse-transcription PCR kit, following manufacturer's protocol19. Statistical analysis: Demographic, clinical data and laboratory test result were entered in Microsoft Excel 2007 and analyzed for finding percentages, proportions, odds ratio, Chi-square test; at 95 per cent confidence interval (95% CI). Attack rate during outbreaks was calculated as described by CDC and expressed for per thousand population20.

Results

In our study, among the investigated DEN outbreaks in four different districts of central India in 2016, three were reported from rural areas and only one from the urban part. Overall positivity was 50.4 per cent as 135 of 268 suspected individuals were tested positive for DEN. Of the 131 samples collected after five days of illness, 30 were positive for CHIKV infection and 13 were positive for both DENV and CHIKV IgM antibodies. Among 135 DEN-positive cases, 75 were tested positive by IgM while 60 by NS1 ELISA (Figure). Serotyping results showed that DENV 3 was the causative agent of outbreaks in rural parts of Damoh, Morena and Sehore districts whereas DENV 2 was responsible for the outbreak in urban areas of Katni district. One sample each was serotyped as DENV 1 and DENV 4 from Damoh and Katni. The IgG studies on NS1-positive samples showed that per cent positivity was higher in urban areas (38.4%) than in rural areas (14.9%), indicating that secondary infections were more prevalent in urban areas. Further, the calculation of attack rates of DENV revealed that urban areas had attack rates of 0.5 per thousand population, while rural areas had attack rates ranging from 2.4 to 38 per thousand population (Table I).
Table I

Cases suspected and found positive for dengue (DEN) during outbreaks by NS1, IgM, IgG ELISA

DistrictSamples testedDEN positiveSerotype detected$IgG per cent$$Attack rate/1000

NS1IgMTotal (%)
Morena (R)76252247 (61.84)DENV-34 (1/25)38
Sehore (R)246713 (54.16)DENV-316.6 (1/6)5.9
Damoh (R)144164056 (38.89)DENV-331.2 (5/16)2.4
Katni (U)2413619 (79.16)DENV-238.4 (5/13)0.5
Total2686075135 (50.4)

$DENV1 and DENV4 detected from one sample each from Damoh and Katni; $$in NS1-positive cases/tested. U, urban; R, rural

Cases suspected and found positive for dengue (DEN) during outbreaks by NS1, IgM, IgG ELISA $DENV1 and DENV4 detected from one sample each from Damoh and Katni; $$in NS1-positive cases/tested. U, urban; R, rural Door-to-door vector surveillance of affected areas by the RRT revealed that unused containers/utensils, cement tanks and water stored in the toilets were the main sites for mosquito breeding in rural areas; whereas, water leftover in air coolers harboured mosquito larva in urban areas. Larvae and pupae were collected from the outbreak areas and identified as Aedes aegypti. The age- and gender-wise stratification of data revealed that males (75, 55.56%) were more affected than females (60, 44.4%), though the difference was not significant. Females in urban areas were found affected significantly higher than in rural areas (P<0.05). Female to male ratio was 1:0.9 in urban areas and 1:1.1 in rural areas. Of the 135 DEN-positive cases, maximum [n=78, (57.8%)] belonged to the age group of 16-45 yr (Table II).
Table II

Age and gender wise dengue positivity distribution of samples collected from DEN outbreak areas

Age group (in yr) MaleFemaleTotal



TestedPositiveTestedPositiveTestedPositive
0-551103154
6-15291520114926
16-458648703015678
46-6014819113319
>6043115158
Total1387513060268135
Age and gender wise dengue positivity distribution of samples collected from DEN outbreak areas Analysis of the symptoms revealed that fever was reported by 116 (86%), chills and rigors by 32 (23.7%), arthralgia by 23 (17%), myalgia by 16 (11.85%), retro-orbital pain was noticed in only two (1.5%) patients and maculopapular rashes and haemorrhage were also the manifestations in two (1.5%) patients each mortality was not reported.

Discussion

In our study, DEN positivity was found to be more than 50 per cent. Similar occurrence of cases during outbreaks has been reported from north, south and western and also from Central India in the past11122122. Co-infection with CHIKV has also been reported earlier23. We detected a higher rate of chikungunya monoinfection as compared to the study done in western India23. This difference in virus circulation might be due to the difference in the environmental conditions and population's susceptibility and immune response of the region. It is well known that synergy of temperature, rainfall and relative humidity promotes abundant vector growth, thus affecting the distribution of serologically confirmed DEN cases2425. Ae. aegypti was incriminated as the vector during outbreaks. Air coolers and water stored in toilets were the most frequently detected breeding sites, and the toilets were the most often missed breeding site by the field workers. Adults in the age group of 16-45 yr and males were predominantly affected. Most studies in India reported DEN as a disease of young adults where males outnumbered females7826. However, Barde et al12 reported that males and females were equally affected in rural MP. The social, behavioural and biological reasons for the specific age group and gender affected need to be evaluated. Serotype of DENV is known to have a role in determining severity of the disease. DENV 2 is reported to be more severe, responsible for causing DHF and mortalities1115, whereas DENV 3 was found more frequently in hospitalized patients than DENV 1 and DENV 416. DENV 2 was the predominant serotype associated with outbreaks, DEN fever and DHF cases between 1970 and 200078. However, DENV 3 is becoming the main serotype in the large outbreaks and sporadic cases of DEN since 2003 in north Indian cities such as Delhi, Gwalior and Lucknow61422. DENV 3 has been reported as the aetiological factor for an outbreak in 2003 from Gwalior, an urban area of northern MP1426. IgG antibodies for DEN can be detected for years after first exposure and detection of IgG in early phase of illness can be used to distinguish between primary and secondary infection1127. Our data showed significantly high positivity of DEN IgG from urban area than from the rural areas, indicating that majority of infections in rural areas during outbreaks were primary. Further, high attack rates were observed in the rural areas; similar findings of higher attack rates during DEN outbreaks from villages of the subcontinent were reported earlies28. Most of the patients exhibited typical clinical picture of DEN as fever, muscular pain, joint pain, rigors, chills, rash and malaise which were found in consensus with earlier studies26. Our study had a limitation of limited number of samples serotyped and IgG tested. However, the important feature of this study was that out of four outbreaks investigated, three were because of DENV 3. In conclusion, our study described epidemiological and clinical aspects related to DEN outbreaks observed in 2016 in Central India. This study also showed that DEN was no more an urban illness; it was rapidly spreading towards the rural areas of Central India with high attack rates. The continuous shift in DENV serotypes during outbreaks can lead to illness of higher severity, thus updating the relevant related information is necessary.
  20 in total

Review 1.  Fifty years of dengue in India.

Authors:  Anita Chakravarti; Rohit Arora; Christine Luxemburger
Journal:  Trans R Soc Trop Med Hyg       Date:  2012-02-21       Impact factor: 2.184

2.  Comparative complete genome analysis of dengue virus type 3 circulating in India between 2003 and 2008.

Authors:  Shashi Sharma; Paban Kumar Dash; Surekha Agarwal; Jyoti Shukla; M M Parida; P V L Rao
Journal:  J Gen Virol       Date:  2011-03-16       Impact factor: 3.891

3.  Circulation of Dengue virus-1 (DENV-1) serotype in Delhi, during 2010-11 after Dengue virus-3 (DENV-3) predominance: a single centre hospital-based study.

Authors:  Ekta Gupta; Sweta Mohan; Meenu Bajpai; Aashish Choudhary; Gaurav Singh
Journal:  J Vector Borne Dis       Date:  2012-06       Impact factor: 1.688

4.  Dengue fever: theories of immunopathogenesis and challenges for vaccination.

Authors:  Melissa M Remy
Journal:  Inflamm Allergy Drug Targets       Date:  2014

5.  Maiden outbreaks of dengue virus 1 genotype III in rural central India.

Authors:  P V Barde; B K Kori; M K Shukla; P K Bharti; G Chand; G Kumar; M J Ukey; N A Ali; N Singh
Journal:  Epidemiol Infect       Date:  2014-03-25       Impact factor: 4.434

6.  Emergence of dengue in tribal villages of Mandla district, Madhya Pradesh, India.

Authors:  P V Barde; M K Shukla; B K Kori; G Chand; L Jain; B M Varun; D Dutta; K Baruah; Neeru Singh
Journal:  Indian J Med Res       Date:  2015-05       Impact factor: 2.375

7.  Serotype influences on dengue severity: a cross-sectional study on 485 confirmed dengue cases in Vitória, Brazil.

Authors:  Creuza Rachel Vicente; Karl-Heinz Herbinger; Günter Fröschl; Camila Malta Romano; Aline de Souza Areias Cabidelle; Crispim Cerutti Junior
Journal:  BMC Infect Dis       Date:  2016-07-08       Impact factor: 3.090

Review 8.  Dengue in India.

Authors:  Nivedita Gupta; Sakshi Srivastava; Amita Jain; Umesh C Chaturvedi
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

9.  Detection of dengue virus 4 from central India.

Authors:  P V Barde; S Godbole; P K Bharti; Gyan Chand; M Agarwal; Neeru Singh
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

10.  Nine year trends of dengue virus infection in Mumbai, Western India.

Authors:  Jayanthi Shastri; Manita Williamson; Nilima Vaidya; Sachee Agrawal; Om Shrivastav
Journal:  J Lab Physicians       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.